Oralight is developing a patent-protected precision photobiomodulation platform for oral mucositis, using a proprietary Optical Surface Applicator to make light therapy more consistent and measurable. Licensed from Roswell Park Comprehensive Cancer Center, the platform uses closed-loop feedback to control delivered light energy and is being developed for a pilot clinical study. Its founding team brings more than 40 years of photonics commercialization experience and multiple successful exits.